PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Every figure this model derived for PVCT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2017-12-31
cash 1,156,915 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,368,884 AssetsCurrent 2026-06-30
current liabilities 7,707,145 LiabilitiesCurrent 2026-06-30
equity -6,275,171 StockholdersEquity 2026-06-30
interest expense 2,972 InterestPaidNet 2026-06-30
ocf -2,425,234 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 336,108 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 1,212,371 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up PVCT on one particular measure came for.

RatioValue
cash operating margin-1002.19
current ratio0.18
current ratio reported0.18
deferred revenue growth-91.96
dilution pct0.11
fcf margin-721.56
interest cover-1541.95
operating margin-1363.45
owner earnings margin-1082.27
revenue growth-45.54
revenue growth per share-45.6
rule of 40-1408.99
sbc pct revenue360.71

What to be careful about

What this model itself distrusts about PVCT's figures. Written by the derivation as it ran, not added afterwards.